HSHenian Sun

Henian Sun

*This is an algorithmically generated author record based on publicly available information.

Henian Sun has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Advantages of mesenteric approach to pancreatoduodenectomy for pancreatic head cancer with invasion of great vessels

    by Mikael G. Abgaryan, Aleksei G. Kotelnikov, Aleksandr N. Polyakov, Ivan G. Avdyukhin, Omar A. Egenov, Henian Sun, Ivan S. Stilidi

    Aim – to compare standard and mesenteric approaches to surgical treatment of patients with pancreatic head cancer invading the portal and/or superior mesenteric veins and to evaluate their advantages. Material and methods. Surgical treatment of 192 patients with pancreatic head cancer with portal and/or superior mesenteric vein invasion was performed. In 43 (22.4%) cases, pancreatoduodenal resection was performed through the mesenteric approach, in the remaining 149 (77.3%) patients, the standard approach to surgical treatment was used. Results. The median duration of operations with the mesenteric approach was 290 min., with the standard one, 300 min., the median blood loss was 1120 ml and 1800 ml, respectively, p=0.0002. No statistically significant differences in the long-term treatment results were found for mesenteric and standard approaches: progression of pancreatic head adenocarcinoma was diagnosed in 48.8% and 49%, respectively; the median overall survival was 24.5 months and 22.3 months; the median progression-free survival was 21.3 months and 22.1 months, respectively. Analysis of long-term treatment results depending on the type of approach and the degree of radicality of surgical intervention showed that the incidence of local relapse with standard access in non-radically operated patients is significantly higher (40.6% vs 7.7%, p = 0.001). Conclusion. The advantages of the mesenteric approach over the standard approach to surgical treatment of patients with pancreatic head cancer with portal and/or superior mesenteric vein invasion are as follows: 1) it makes it possible to assess the prevalence and operability of the tumor as early as at the beginning of the surgical intervention; 2) it ensures a significantly higher frequency of operations in the R0 volume; 3) it ensures significantly less blood loss during surgery; 4) after circular resection of the main veins it provides more opportunities to perform end-to-end plastic surgery, which reduces the risk of thrombosis due to the formation of only one anastomosis and reduces the time of clamping of the main veins, reducing the risk of liver and intestinal ischemia.

  • Frequency of MSI, PD-L1 (CPS), HER2 in poorly cohesive gastric carcinomas

    by S.N. Nered, R.O. Torosyan, N.A. Kozlov, H. Sun, I.G. Avdyukhin, P.V. Kononets, I.S. Stilidi

    Gastric cancer (GC) is a heterogeneous tumor with various molecular changes. An active search for molecular markers is crucial to determine the effectiveness of drug treatment and prognosis of the disease. Several biomarkers have the greatest clinical significance: HER2, MSI / dMMR, PD-L1 (CPS), EBV and Claudin 18. Objective. To study the frequency of HER2, MSI / dMMR and PD-L1 (CPS) in patients with operable GC depending on the tumor type according to P. Lauren. Material and methods. The study included 600 patients with GC who underwent radical surgical treatment at the N.N. Blokhin National Medical Research Center of Oncology from 2018 to 2023. Results. In the study, the proportion of diffuse GC was 21.5% (120/600). HER2 overexpression was found in 5.2% (5/96) of cases with diffuse GC, 20.4% (37/181) of cases with intestinal GC, 10.1% (7/69) of cases with mixed GC (p=0.0029). The incidence of MSI was 3.3% (4/120) of cases with diffuse GC, 11.2% (28/251) of cases with intestinal GC, 7.3% (7/97) of cases with mixed GC (p=0.0378). PD-L1 expression (CPS> 1) was found in 42.3% (11/26) of cases with diffuse GC, 59.4% (35/59) of cases with intestinal GC, 27.3% (9/33) of cases with mixed GC (p=0.006). In poorly cohesive/signet ring cell cancer MSI occurred in 2.5% (2/79) of cases; HER2 overexpression — in 2.9% (2/68) of cases; PD-L1 (CPS> 1) — in 42.1% (8/19) of cases. Conclusion. Our study demonstrated that in diffuse and poorly cohesive/signet ring cell GC the frequency of occurrence of the above clinically significant tumor biomarkers is lower compared to intestinal/mixed GC.


  • Open Access

    Prognosis of distal diffuse gastric cancer depending on the extent of surgical procedure

    by Rafael O. Torosyan, Sergei N. Nered, Nikolai A. Kozlov, Sun Henian, Pavel V. Kononets, Ivan S. Stilidi

    Aim – to study the clinical and morphological characteristics and conduct a comparative assessment of the survival of patients with locally advanced distal diffuse gastric cancer depending on the type of the surgical procedure. Material and methods. We performed a retrospective review of the impact of the extent of surgery in the prognosis of 125 patients with diffuse gastric cancer of distal localization, who underwent total gastrectomy or distal subtotal gastrectomy at the N.N. Blokhin National Medical Research Center of Oncology in the period from 2005 to 2022. Results. The depth of tumor invasion (T4), the lymph node status, and the tumor stage had a significant negative prognostic value in the univariate analysis. Resection margin (R1) tended to significantly affect the overall survival (p=0.082). The extent of the surgical procedure did not affect overall survival in the univariate analysis (p=0.75). The multivariate analysis revealed that only the tumor stage had a relative effect on the overall survival. In the distal gastrectomy group, the median overall survival and the 5-year OS rates were 85.0 months, 58.8% (95% CI: 0.487-0.711). In the total gastrectomy group, the median overall survival, 5-year OS rates were 89.0 months, 60.3% (95% CI: 0.460-0.791). However, the differences were statistically insignificant (p=0.75). In patients in the distal subtotal gastrectomy group, the recurrence was detected in 12.7% of all cases of recurrence (8/63): 6 of them with intramural recurrence and 2 of them with intramural and distant recurrence of the disease. In patients in the total gastrectomy group, intramural recurrence was found only in one patient (4.8%) in the esophago-enteroanastomosis. Conclusions. Overall survival and relapse-free survival rates in patients with diffuse cancer of distal localization after total and distal subtotal gastrectomy do not have significant differences. However, distal subtotal gastrectomy in this category of patients is associated with a higher risk of local recurrence (12.7%) and can not be recommended as an alternative to total gastrectomy in patients with satisfactory functional status.

  • Open Access

    Pathological complete response after neoadjuvant immunochemotherapy in gastric cancer with microsatellite instability without PD-L1 expression (CPS = 0). A case report

    by S. N. Nered, R. N. Dzamaliddinova, Хэнянь Сунь, А. А. Tryakin, P. V. Kononets, I. S. Stilidi

    Despite the use of modern treatment methods for gastric cancer (GC), survival rates in locally advanced stages remain unsatisfactory. This necessitates the search for new therapeutic options and potential predictive factors for tailoring treatment approaches. The emergence of new molecular classifications like The Cancer Genome Atlas (TCGA) and the Asian Cancer Research Group (ACRG), leading to the identification of a distinct subset — gastric cancer with high microsatellite instability (MSI-H) caused by mismatch repair deficiency (dMMR), has paved the way for a novel treatment direction: immunotherapy. MSI status and PD-L1 expression are regarded as predictors of immunotherapy efficacy in GC. However, the question of which marker is more accurate or if they should be considered together remains unanswered. Furthermore, the efficacy of checkpoint inhibitor therapy is often attributed to increased PD-L1 expression in microsatellite unstable tumors compared to microsatellite stable ones. The article discusses a case demonstrating the high efficacy of immunochemotherapy, resulting in complete pathomorphological regression of the tumor in a patient with locally advanced gastric cancer and MSI-H status after neoadjuvant immunochemotherapy, despite the absence of PD-L1 expression (CPS-0). The patient has been monitored for 1.5 years post-treatment at the N. N. Blokhin National Medical Research Center of Oncology without signs of progression.


  • Open Access

    Prognosis of early and advanced signet ring cell gastric carcinoma compared with other histological subtypes

    by R. O. Torosyan, S. N. Nered, N. A. Kozlov, Henian Sun, P. V. Kononets, I S. Stilidi

    Background. Signet ring cell gastric carcinoma of the stomach traditionally characterized by its poor prognosis. Survival of patients with signet ring cell gastric carcinoma regardless of the stage of the disease has not been well studied.Aim. To compare clinicopathological characteristics and survival of the patients with signet ring cell gastric carcinoma of the stomach and non-signet ring cell carcinoma depending on the stage of the disease.Materials and methods. We performed retrospective review was undertaken of patients with gastric cancer who received surgical treatment in period from 2013–2018.Results. At early signet ring cell cancer, the 3and 5-year survival rates was 100,0 and 89.0 %; for non-signet ring cell carcinoma 91.4 and 85.3 % (р = 0.6; Hazard Ratio (HR) 0.73; 95 % Confidence Interval (CI) 0.22–2.42) respectively. For advanced signet ring cell carcinoma, the median survival rates, 3and 5-year survival rates was 38 months, 53.0 and 38.4 %; for non-signet ring cell carcinoma 51.1 months, 59.2 and 48.0 % (р = 0.2; HR 1.2; 95 % CI 0.91–1.54).Conclusion. Long-term results in patients with early (T1) signet ring cell cancer of the stomach did not significantly differ in comparison with other histological types of gastric cancer. Long-term results of advanced signet ring cell cancer are worse than non-signet ring cell cancer, but the differences are not statistically significant.


  • Open Access

    The results of treatment for resectable gastric cancer with microsatellite instability

    by H. Sun, S. N. Nered, A. A. Tryakin, E. V. Artamonova, A. E. Kalinin, V. E. Bugaev, A. M. Stroganova, N. S. Besova, P. P. Arkhiri, V. I. Marshall, et al.

    Background. microsatellite instability (MSI) is a prognostic marker of survival in many malignant diseases and show resistance to chemotherapy at early stages of colorectal cancer and show no benefits from chemotherapy at early stages of colorectal cancer. However, the role of MSI in resectable gastric cancer (GC) remains unknown.Aim. To study the results of treatment of resectable gastric cancer with microsatellite instability.Materials and methods. The study included 286 patients with resectable gC who received treatment at the N. N. Blokhin national medical Research Center of Oncology. All patients underwent PCR testing for MSI-H in 5 markers (BAT25, BAT26, NR21, NR24, NR27). Tumor regression grades (TRG) were evaluated according to the mandard tumour regression score, including disease-free survival and overall survival.Results. MSI indicated in 27 cases (9.44 %) out of 286 resectable gastric cancer. In group patients who received only surgical treatment, 2-year disease-free survival in patients with MSI-H was 77.80 % versus 88.29 % in MSS patients (hazard ratio (HR) 1.82, 95 % confidence interval (CI) 0.37–8.82, p = 0.45), 2-year overall survival in patients with MSI-H was 88.90 % versus 95.36 % in MSS patients (HR 2.03, 95 % CI 0.20–19.8, p = 0.54). In patients who received perioperative chemotherapy, 28.57 % (4 / 14) had progression in MSI-H tumor versus 3.61 % (6 / 166) in MSS tumor (p 0.001). In group patients who received treatment combined with chemotherapy, 2-year disease-free survival in patients with MSI-H was 59.60 % versus 67.36 % (HR 1.96, CI 95 % 0.88–4.35, p = 0.09), 2-year overall survival in patients with MSI-H was 67.30 % versus 85.86 % in MSS patients (HR 1.86, 95 % CI 0.64–5.41, p = 0.25)Conclusion. MSI-H is not a favorable prognosis factor in patients with resectable GC who are treated surgically combined with chemotherapy. The prevalence of progression in patients with MSI-H-status is higher than MSS-status with perioperative chemotherapy (FLOT / FOLFIRINOX).